Drug Trial Radar · NCT01899053
A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies
Last checked: Nov 19, 2026Latest source record: Oct 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Jun 28, 2013
Primary completion
Jan 31, 2017
Study completion Apr 30, 2018
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Jul 15, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the safety and to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and dosing schedules of oral TAK-228+TAK-117. It also evaluated the single- and multiple-dose plasma pharmacokinetics (PK) of TAK-228+TAK-117 in participants with advanced nonhematologic malignancies.
Conditions
- Advanced Nonhematologic Malignancies
Interventions
TAK-228Drug
TAK-228 Capsules
TAK-117Drug
TAK-117 Capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)Time frame: From Baseline to 30 days after the last dose of study drug (Up to approximately 68 weeks)
- Tmax: Time to Reach the Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- RAC: Accumulation Ratio for TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- Peak to Trough Ratio for TAK-228 After Single-dose and Multiple-dose of TAK-228 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- Cmax: Maximum Observed Plasma Concentration After Single-dose and Multiple-dose of TAK-117 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- Terminal Phase Elimination Half-life (T1/2) After Single-dose and Multiple-dose of TAK-117 in Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration After Single-dose and Multiple-dose of TAK-117 in Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- RAC: Accumulation Ratio for TAK-117 in the Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- Peak to Trough Ratio After Single-dose and Multiple-dose of TAK-117 in Dose Escalation CohortTime frame: Cycle 1: Days 1 and 24 predose and at multiple timepoints (up to 24 hours) postdose
- Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
- Cmax: Maximum Observed Plasma Concentration for TAK-228 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
- AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-228 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
- Terminal Phase Elimination Half-life (T1/2) for TAK-228 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
- CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-228 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
- Peak to Trough Ratio for TAK-228 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 10 predose and at multiple timepoints (up to 24 hours) postdose
- Tmax: Time to Reach the Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
- Cmax: Maximum Observed Plasma Concentration for TAK-117 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
- AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Observed Quantifiable Concentration for TAK-117 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
- Terminal Phase Elimination Half-life (T1/2) for TAK-117 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
- CL/F: Apparent Clearance After Extravascular Administration, Calculated Using the Observed Value of the Last Quantifiable Concentration for TAK-117 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
- Peak to Trough Ratio for TAK-117 in DDI Expansion CohortTime frame: Cycle 1, Day 3 predose and at multiple timepoints (up to 8 hours) postdose; Cycle 1, Day 17 predose and at multiple timepoints (up to 24 hours) postdose
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Boston, Massachusetts
Site not named
Nashville, Tennessee
Site not named
San Antonio, Texas
Site not named
Barcelona, Spain
Site not named
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.